CRISPR Therapeutics (CRSP) Competitors $47.91 -2.52 (-5.00%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$47.75 -0.16 (-0.33%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CRSP vs. MRNA, NBIX, TECH, PCVX, EXEL, QGEN, RGEN, HALO, RVMD, and KRYSShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Moderna (MRNA), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Vaxcyte (PCVX), Exelixis (EXEL), Qiagen (QGEN), Repligen (RGEN), Halozyme Therapeutics (HALO), Revolution Medicines (RVMD), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry. CRISPR Therapeutics vs. Moderna Neurocrine Biosciences Bio-Techne Vaxcyte Exelixis Qiagen Repligen Halozyme Therapeutics Revolution Medicines Krystal Biotech CRISPR Therapeutics (NASDAQ:CRSP) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the MarketBeat Community favor CRSP or MRNA? CRISPR Therapeutics received 265 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 64.52% of users gave CRISPR Therapeutics an outperform vote while only 54.43% of users gave Moderna an outperform vote. CompanyUnderperformOutperformCRISPR TherapeuticsOutperform Votes48064.52% Underperform Votes26435.48% ModernaOutperform Votes21554.43% Underperform Votes18045.57% Which has better valuation & earnings, CRSP or MRNA? CRISPR Therapeutics has higher earnings, but lower revenue than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$37.31M110.14-$366.25M-$4.37-10.96Moderna$3.24B4.23-$3.56B-$9.28-3.83 Do analysts rate CRSP or MRNA? CRISPR Therapeutics currently has a consensus price target of $74.40, indicating a potential upside of 55.29%. Moderna has a consensus price target of $60.63, indicating a potential upside of 70.65%. Given Moderna's higher probable upside, analysts plainly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 1 Sell rating(s) 9 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.50Moderna 4 Sell rating(s) 15 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Is CRSP or MRNA more profitable? Moderna has a net margin of -110.04% compared to CRISPR Therapeutics' net margin of -981.54%. CRISPR Therapeutics' return on equity of -18.46% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-981.54% -18.46% -15.79% Moderna -110.04%-28.74%-21.83% Does the media prefer CRSP or MRNA? In the previous week, CRISPR Therapeutics had 16 more articles in the media than Moderna. MarketBeat recorded 58 mentions for CRISPR Therapeutics and 42 mentions for Moderna. CRISPR Therapeutics' average media sentiment score of 0.37 beat Moderna's score of 0.21 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 8 Very Positive mention(s) 6 Positive mention(s) 27 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral Moderna 14 Very Positive mention(s) 2 Positive mention(s) 13 Neutral mention(s) 6 Negative mention(s) 3 Very Negative mention(s) Neutral Do institutionals & insiders believe in CRSP or MRNA? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 15.7% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, CRSP or MRNA? CRISPR Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. SummaryCRISPR Therapeutics beats Moderna on 12 of the 19 factors compared between the two stocks. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.11B$3.12B$5.80B$8.95BDividend YieldN/A1.57%4.78%3.85%P/E Ratio-10.9630.1126.4518.81Price / Sales110.14319.76450.0676.66Price / CashN/A183.5344.0437.47Price / Book2.133.567.634.64Net Income-$366.25M-$71.72M$3.18B$245.69M7 Day Performance-3.64%-2.44%-1.85%-2.63%1 Month Performance15.42%0.36%0.19%-2.37%1 Year Performance-41.86%-11.49%17.21%13.64% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics3.1671 of 5 stars$47.91-5.0%$74.40+55.3%-41.9%$4.11B$37.31M-10.96473Analyst ForecastInsider TradeOptions VolumeAnalyst RevisionMRNAModerna4.7336 of 5 stars$32.99+3.4%$66.89+102.8%-59.4%$12.70B$6.85B-5.675,600Analyst DowngradeOptions VolumeHigh Trading VolumeNBIXNeurocrine Biosciences4.9717 of 5 stars$115.02-1.6%$166.90+45.1%-7.6%$11.65B$2.36B34.961,400Analyst DowngradeBuyback AnnouncementAnalyst RevisionGap UpTECHBio-Techne4.9274 of 5 stars$65.94-1.2%$86.57+31.3%-9.5%$10.48B$1.16B66.613,100Analyst DowngradeInsider TradePCVXVaxcyte2.5871 of 5 stars$84.00+0.2%$127.71+52.0%+10.4%$10.47BN/A-18.26160Insider TradePositive NewsEXELExelixis4.6306 of 5 stars$35.00+1.5%$37.24+6.4%+77.8%$10.00B$1.83B22.441,310Analyst UpgradeInsider TradeQGENQiagen4.4259 of 5 stars$39.85-0.5%$48.78+22.4%-5.2%$8.84B$1.98B110.975,967Analyst DowngradeRGENRepligen4.275 of 5 stars$146.92+0.5%$182.91+24.5%-18.1%$8.23B$638.76M-397.071,783Earnings ReportAnalyst ForecastNews CoverageHALOHalozyme Therapeutics4.4455 of 5 stars$58.29-0.5%$60.89+4.5%+50.5%$7.42B$829.25M19.30390Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRVMDRevolution Medicines4.5103 of 5 stars$40.67-1.6%$66.25+62.9%+41.7%$6.84B$11.58M-11.33250Positive NewsKRYSKrystal Biotech4.4745 of 5 stars$153.24-1.6%$206.67+34.9%+73.9%$4.41B$50.70M86.58210Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Moderna Alternatives Neurocrine Biosciences Alternatives Bio-Techne Alternatives Vaxcyte Alternatives Exelixis Alternatives Qiagen Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Revolution Medicines Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRSP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
